利伐沙班市場：依適應症、劑型、病患類型、通路和地區分類

2025 年全球利伐沙班市場規模估計為 1,790 萬美元，預計 2032 年將達到 2,830 萬美元，2025 年至 2032 年的複合年成長率為 6.8%。

數字。 2025 年利伐沙班各地區市場佔有率（%）

過去十年，受全球深層靜脈栓塞症和肺動脈栓塞盛行率不斷上升的推動，利伐沙班的全球市場穩步成長。利伐沙班是一種口服抗凝血劑，可作為血液凝固途徑中Xa因子的抑制劑。對於需要抗凝血治療的患者，利伐沙班可作為Warfarin的替代品。此藥最常用於降低非瓣膜性心房顫動患者發生中風和全身性栓塞的風險，治療深層靜脈栓塞症和肺動脈栓塞，以及預防復發性靜脈血栓栓塞症。隨著人們對新型口服抗凝血藥物益處的認知不斷提高以及患有目標疾病的患者數量不斷增加，利伐沙班市場預計將在未來幾年繼續快速擴張。

市場動態

全球利伐沙班市場的成長是由於老年人口的增加，他們更容易發生血栓性栓塞症，人們對新型口服抗凝血劑的偏好日益增加，而非Warfarin等傳統藥物，以及世界各地實施的外科手術數量不斷增加。然而，與學名藥相比，利伐沙班治療的成本較高，這是限制其廣泛使用的主要因素。從積極的一面來看，評估利伐沙班用於更多適應症的臨床試驗正在進行中，而新年齡層的核准有望創造新的機會。此外，開發適合特定患者類型的改良劑型可以克服高成本帶來的挑戰。

研究的主要特點

• 本報告對全球利伐沙班市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了關於市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。
• 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球利伐沙班市場的主要企業概況。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球利伐沙班市場報告針對該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員將透過分析全球利伐沙班市場所使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購情景

4. 2025 年至 2032 年全球Rivaroxaban市場（依適應症分類）（百萬美元）

• 介紹
• 心房顫動
• 深層靜脈栓塞症（DVT）
• 肺動脈栓塞（PE）
• 預防靜脈血栓栓塞症(VTE)
• 其他（急性冠狀動脈症候群等）

5. 2025-2032 年全球Rivaroxaban市場（以劑型分類）（百萬美元）

• 介紹
• 錠劑
• 暫停

6. 2025-2032 年全球利伐沙班市場按病患類型分類（百萬美元）

• 介紹
• 成人
• 孩子們

7. 2025-2032 年全球利伐沙班市場按分銷管道分類（百萬美元）

• 介紹
• 醫院和診所
• 零售藥局
• 網路藥局

第 8 章 2020-2032 年全球利伐沙班市場，按地區分類，金額（百萬美元）

• 介紹
• 北美洲
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 阿根廷
• 墨西哥
• 其他拉丁美洲國家
• 歐洲
• 德國
• 英國
• 西班牙
• 法國
• 義大利
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 中國
• 印度
• 日本
• 澳洲
• 韓國
• 東南亞國協
• 其他亞太地區
• 中東
• 海灣合作理事會國家
• 以色列
• 其他中東地區
• 非洲
• 南非
• 北非
• 中部非洲

第9章 競爭格局

• Bayer AG
• Janssen Pharmaceuticals, Inc.
• Interquim SA
• Natco Pharma
• Mylan NV
• 山德士（諾華旗下的一個部門）
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Zydus Cadila
• Apotex Inc.
• Hetero Labs Limited
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals
• Reddy's Laboratories
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Pfizer Inc.
• Eisai Co., Ltd.
• Amgen Inc.

第 10 章分析師建議

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global Rivaroxaban Market is estimated to be valued at USD 17.9 Mn in 2025 and is expected to reach USD 28.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Figure. Rivaroxaban Market Share (%), By Region 2025

The global Rivaroxaban market has been growing steadily over the past decade on the back of rising prevalence of deep vein thrombosis and pulmonary embolism disorders globally. Rivaroxaban is an oral anticoagulant that acts as an inhibitor of factor Xa in the blood coagulation pathway. It has emerged as a preferred alternative to warfarin for patients requiring anticoagulation therapy due to advantages such as fixed dosing without need for frequent monitoring. The drug is most commonly used to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and reduce recurrence of venous thromboembolism. With growing awareness about benefits of novel oral anticoagulants and increasing patient pool affected by target diseases, the rivaroxaban market is anticipated to continue expanding rapidly over the coming years.

Market Dynamics:

The global rivaroxaban market growth is driven by rising geriatric population who are more prone to thromboembolic disorders, growing preference for novel oral anticoagulants over traditional drugs like warfarin, and increasing number of surgical procedures performed worldwide. However, high costs associated with rivaroxaban therapy compared to generic drugs is a major factor limiting its widespread adoption. On the positive side, ongoing clinical trials evaluating rivaroxaban for additional indications and approval for new age groups are expected to create new opportunities. Moreover, development of modified dosage forms suited for specific patient types could help overcome challenges posed by high costs.

Key features of the study:

• This report provides in-depth analysis of the global rivaroxaban market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global rivaroxaban market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Pfizer, Bayer, and Sanofi
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rivaroxaban market.

Detailed Segmentation:

• By Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Atrial Fibrillation
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Prophylaxis of Venous Thromboembolism (VTE)
  • Others (Acute Coronary Syndrome, etc.)
• By Formulation Insights (Revenue, USD Mn, 2020 - 2032)
  • Tablets
  • Suspension
• By Patient Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Adults
  • Pediatrics
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals and Clinics
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • Interquim SA
  • Natco Pharma
  • Mylan N.V.
  • Sandoz (a Novartis division)
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Zydus Cadila
  • Apotex Inc.
  • Hetero Labs Limited
  • Fresenius Kabi AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Reddy's Laboratories
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eisai Co., Ltd.
  • Amgen Inc.

Table of Contents

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

• Research Objectives
• Assumptions
• Abbreviations

2. MARKET PURVIEW

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Rivaroxaban Market, By Indication
  • Global Rivaroxaban Market, By Formulation
  • Global Rivaroxaban Market, By Patient Type
  • Global Rivaroxaban Market, By Distribution Channel
  • Global Rivaroxaban Market, By Region

3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Rivaroxaban Market, By Indication, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Atrial Fibrillation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Deep Vein Thrombosis (DVT)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Pulmonary Embolism (PE)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Prophylaxis of Venous Thromboembolism (VTE)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Acute Coronary Syndrome, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Rivaroxaban Market, By Formulation, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Suspension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Rivaroxaban Market, By Patient Type, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Pediatrics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Rivaroxaban Market, By Distribution Channel, 2025-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Rivaroxaban Market, By Region, 2020 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
• South Africa
• North Africa
• Central Africa

9. COMPETITIVE LANDSCAPE

• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Interquim SA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Natco Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sandoz (a Novartis division)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aurobindo Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zydus Cadila
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Apotex Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hetero Labs Limited
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals
• Reddy's Laboratories
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Pfizer Inc.
• Eisai Co., Ltd.
• Amgen Inc.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us